STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. My backyard tortoise, Philbert, has for some reason chosen my closet as his preferred brumation burrow. This is not advisable, I am told. Anyone know how to properly accommodate a wayward Russian tortoise? Telehealth companies push GLP-1s for addiction treatment GLP-1 drugs are showing promise as treatments for addiction, particularly alcohol use disorder — and some telehealth companies aren’t waiting for the FDA to weigh in, STAT’s Katie Palmer writes. Startups including Quel, Livelyhood, and Choose Your Horizon are already marketing off-label prescriptions of the popular obesity drugs to people struggling with substance use. Sometimes, they’re even offering compounded versions that haven’t been approved by regulators. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe